Life Sciences

FDA releases draft guidance for trials of incontinence devices

Device Regulation Alert: Safety, Compliance and Reimbursement News, September 26, 2008

Medical device manufacturers should use a randomized, controlled trial to collect data to demonstrate the safety and effectiveness of urinary incontinence devices, according to FDA draft guidance.

Clinical studies may not be needed for most class I and II urinary incontinence devices, but FDA recommends manufacturers collect clinical data for class I and II urinary incontinence devices with any one of the following:

  • Indications for use dissimilar from a legally marketed device of the same type
  • Designs dissimilar from designs previously cleared under a premarket notification
  • New technology

Manufacturers need clinical data with valid scientific evidence for class III devices. The guidance includes a list of devices and their classifications. The FDA also details how manufacturers should design and conduct studies.



0 comments on “FDA releases draft guidance for trials of incontinence devices


    ePharm5 InDepth
  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Complete Guide to Lab Safety, 3rd Ed.

    The third edition of this popular resource makes training and compliance easier by consolidating regulations from all...

Most Popular